Altimmune advances pemvidutide for metabolic disorders treatment

Altimmune, Inc. is making progress with its drug pemvidutide, which targets metabolic dysfunction associated with obesity. Recent developments highlight its potential advantages in treating metabolic-associated fatty liver disease (MAFLD). The company previously discussed pemvidutide's competitive edge in the market. New findings suggest it may offer significant benefits over existing treatments, enhancing its position in the pharmaceutical landscape. Altimmune continues to focus on advancing pemvidutide's development, aiming to address unmet needs in the treatment of metabolic disorders.